Urgent interim commissioning policy: Peginterferon alfa-2a and ropeginterferon alfa-2b to treat myeloproliferative neoplasms

Document first published:
Page updated:
Topic:
Publication type:

NHS England has confirmed that peginterferon alfa-2a and ropeginterferon alfa-2b will be made available as treatment options for people with myeloproliferative neoplasms (MPNs) within the criteria set out in this urgent interim commissioning policy position during the period of supply disruption of peginterferon alfa-2a which is expected to be until July 2025.